Wolff-Parkinson-White syndrome drug prophylaxis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Wolff-Parkinson-White syndrome}} | {{Wolff-Parkinson-White syndrome}} | ||
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}} | {{CMG}}; '''Associate Editor-In-Chief:''' {{ Sara.Zand}} {{CZ}} | ||
==Overview== | |||
Oral [[beta-blocker]], [[diltiazem]], and [[verapamil]] for prevention of [[AVRT]] in patients without preexcitation in resting [[ECG]]. Oral [[flecainide]] and [[propaphenone]] in patients with preexcitation in resting [[ECG]] that are not candidates for catheter ablation and do not have structural or [[ischemic heart disease]]. | |||
==Drug Prophylaxis In The Patient With Proven Tachyarrhythmias== | ==Drug Prophylaxis In The Patient With Proven Tachyarrhythmias== | ||
* Oral [[beta-blocker]], [[diltiazem]], and [[verapamil]] for prevention of [[AVRT]] in patients with out preexcitation in resting [[ECG]]. | |||
* Oral [[flecainide]] and [[propaphenone]] in patients with preexcitation in resting [[ECG]] that are not candidates for catheter ablation and do not have structural or [[ischemic heart disease]].<ref name="PageJoglar2016">{{cite journal|last1=Page|first1=Richard L.|last2=Joglar|first2=José A.|last3=Caldwell|first3=Mary A.|last4=Calkins|first4=Hugh|last5=Conti|first5=Jamie B.|last6=Deal|first6=Barbara J.|last7=Estes III|first7=N.A. Mark|last8=Field|first8=Michael E.|last9=Goldberger|first9=Zachary D.|last10=Hammill|first10=Stephen C.|last11=Indik|first11=Julia H.|last12=Lindsay|first12=Bruce D.|last13=Olshansky|first13=Brian|last14=Russo|first14=Andrea M.|last15=Shen|first15=Win-Kuang|last16=Tracy|first16=Cynthia M.|last17=Al-Khatib|first17=Sana M.|title=2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia|journal=Heart Rhythm|volume=13|issue=4|year=2016|pages=e136–e221|issn=15475271|doi=10.1016/j.hrthm.2015.09.019}}</ref> | |||
==References== | ==References== | ||
Latest revision as of 08:57, 12 November 2020
|
Wolff-Parkinson-White syndrome Microchapters |
|
Differentiating Wolff-Parkinson-White syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Wolff-Parkinson-White syndrome drug prophylaxis On the Web |
|
Risk calculators and risk factors for Wolff-Parkinson-White syndrome drug prophylaxis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Sara Zand, M.D.[2] Cafer Zorkun, M.D., Ph.D. [3]
Overview
Oral beta-blocker, diltiazem, and verapamil for prevention of AVRT in patients without preexcitation in resting ECG. Oral flecainide and propaphenone in patients with preexcitation in resting ECG that are not candidates for catheter ablation and do not have structural or ischemic heart disease.
Drug Prophylaxis In The Patient With Proven Tachyarrhythmias
- Oral beta-blocker, diltiazem, and verapamil for prevention of AVRT in patients with out preexcitation in resting ECG.
- Oral flecainide and propaphenone in patients with preexcitation in resting ECG that are not candidates for catheter ablation and do not have structural or ischemic heart disease.[1]
References
- ↑ Page, Richard L.; Joglar, José A.; Caldwell, Mary A.; Calkins, Hugh; Conti, Jamie B.; Deal, Barbara J.; Estes III, N.A. Mark; Field, Michael E.; Goldberger, Zachary D.; Hammill, Stephen C.; Indik, Julia H.; Lindsay, Bruce D.; Olshansky, Brian; Russo, Andrea M.; Shen, Win-Kuang; Tracy, Cynthia M.; Al-Khatib, Sana M. (2016). "2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia". Heart Rhythm. 13 (4): e136–e221. doi:10.1016/j.hrthm.2015.09.019. ISSN 1547-5271.